Live price temporarily unavailable.
Metagenomi Therapeutics (MGX) is a Health Care company. Latest news and coverage below.
| FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|
| Income statement | |||
| Revenue | $44.8M | $52.3M | $25.2M |
| Growth (year over year) | — | +16.8% | −51.8% |
| Operating income | −$78.5M | −$88.9M | −$96.0M |
| Operating margin | −175.4% | −170.0% | −380.9% |
| Net income | −$68.3M | −$78.1M | −$87.9M |
| Net margin | −152.5% | −149.3% | −348.5% |
| EPS (diluted) | −$20.05 | −$2.36 | −$2.36 |
| Balance sheet | |||
| Cash and equivalents | $140.6M | $27.4M | $41.7M |
| Total assets | $364.8M | $324.6M | $221.1M |
| Total liabilities | $149.7M | $89.7M | $62.5M |
| Shareholders' equity | −$135.6M | $234.9M | $158.6M |
| Cash flow | |||
| Operating cash flow | −$91.4M | −$109.1M | −$88.9M |
| Capital expenditure | $9.81M | $3.11M | $574.0K |
| Free cash flow | −$101.2M | −$112.2M | −$89.5M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $11.5M | $9.61M | $4.13M | $8.51M | $8.66M | $3.91M | $1.25M | — |
| Growth (year over year) | −6.9% | −22.5% | −63.0% | −57.5% | −24.8% | −59.3% | −69.8% | — |
| Operating income | −$22.4M | −$20.6M | −$27.8M | −$21.0M | −$22.8M | −$24.4M | −$24.6M | −$28.8M |
| Operating margin | −194.4% | −214.5% | −674.1% | −246.5% | −263.8% | −623.0% | −1970.1% | — |
| Net income | −$18.8M | −$23.4M | −$25.0M | −$19.9M | −$20.4M | −$22.5M | −$23.1M | −$27.5M |
| Net margin | −163.0% | −243.4% | −606.7% | −233.9% | −235.5% | −576.0% | −1847.7% | — |
| EPS (diluted) | −$0.51 | −$0.37 | −$0.68 | −$0.54 | −$0.55 | −$0.59 | −$0.61 | −$0.73 |
| Balance sheet | ||||||||
| Cash and equivalents | $25.1M | $27.4M | $29.2M | $26.9M | $32.8M | $41.7M | $25.3M | $39.0M |
| Total assets | $358.3M | $324.6M | $297.9M | $272.3M | $247.9M | $221.1M | $197.0M | $173.7M |
| Total liabilities | $102.6M | $89.7M | $85.2M | $76.5M | $69.5M | $62.5M | $59.2M | $61.1M |
| Shareholders' equity | $255.8M | $234.9M | $212.7M | $195.8M | $178.4M | $158.6M | $137.8M | $112.6M |
| Cash flow | ||||||||
| Operating cash flow | −$26.6M | −$26.3M | −$22.8M | −$21.3M | −$21.3M | −$23.5M | −$21.2M | −$19.5M |
| Capital expenditure | $1.20M | $334.0K | $288.0K | $127.0K | $74.0K | $85.0K | $25.0K | $125.0K |
| Free cash flow | −$27.8M | −$26.6M | −$23.1M | −$21.4M | −$21.3M | −$23.6M | −$21.2M | −$19.6M |
From Metagenomi Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Metagenomi Therapeutics in our feed yet.